Section Arrow
COGT.NASDAQ
- Cogent Biosciences
Quotes are at least 15-min delayed:2026/01/07 16:05 EST
After Hours
Last
 36.27
0 (0.00%)
Bid
36.23
Ask
36.5
High 36.99 
Low 36.27 
Volume 39.94K 
Regular Hours (Closed)
Last
 36.48
+1.7 (+4.89%)
Day High 
37.004983 
Prev. Close
34.78 
1-M High
43.73 
Volume 
3.43M 
Bid
36.23
Ask
36.5
Day Low
34.5 
Open
35.22 
1-M Low
32.93 
Market Cap 
5.34B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 37.25 
20-SMA 38.49 
50-SMA 32.72 
52-W High 43.73 
52-W Low 3.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.05/-1.71
Enterprise Value
5.35B
Balance Sheet
Book Value Per Share
1.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1316+0.0266+25.33%-- 
After Hours 0.1256 0 0.00%
ERASErasca5.425+1.795+49.45%-- 
After Hours 4.5 -0.67 -12.96%
RXRXRecursion Pharmaceuticals4.885+0.335+7.36%-- 
After Hours 4.83 -0.02 -0.41%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
After Hours 13.7381 +0.0081 +0.06%
GLUEMonte Rosa Therapeutics23.3816+7.3716+46.04%54.09PE
After Hours 22.92 -0.36 -1.55%
Industry overview quotes are at least 15 minutes delayed
Business Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.